UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
August 21, 2008
Date of Report (Date of Earliest Event Reported)
POLYMEDIX, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 000-51895 | | 27-0125925 |
| (State or other jurisdiction | | (Commission File Number) | | (IRS Employer |
| of incorporation) | | | | Identification No.) |
| | | |
| 170 N. Radnor Chester Road | | |
| Suite 300 | | |
| Radnor, PA | | 19087 |
| (Address of principal executive offices) | | (Zip Code) |
484-598-2400
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| | |
| Item 7.01. | | Regulation FD Disclosure. |
PolyMedix, Inc. (OTC BB: PYMX) announced that it has initiated dosing and commenced a Phase I clinical study in Canada for its PMX-30063 defensin mimetic antibiotic compound. A copy of the press release is attached to this report as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Report, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. The information in this Report will not be deemed as an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
| | |
| Item 9.01. | | Financial Statements and Exhibits. |
| | | | | |
| (d) Exhibit No. | | Description |
| | | | | |
| | 99.1 | | | Press Release issued August 21, 2008 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | POLYMEDIX, INC.
| |
| Date: August 21, 2008 | By: | /s/ Edward F. Smith | |
| | | Name: | Edward F. Smith | |
| | | Title: | Vice President, Finance and
Chief Financial Officer | |
| |
Exhibit Index
| | | | | |
| Exhibit No. |
| | | | | |
| | 99.1 | | | Press Release, dated August 21, 2008, issued by PolyMedix, Inc. |
